AmacaThera is developing a unique, injectable hydrogel platform technology for a wide range of medical applications. It’s first product aims to reduce the need for opioids and provide sustained relief for post-operative pain.
BioTheryX is a clinical-stage company with expertise in Targeted Protein Degradation with their novel, small molecule PHM to restore protein homeostasis and treat a wide range of diseases and serious cancers AML and MDS.
Bright Angel Therapeutics is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections.
Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company developing a novel therapy to restore smell and flavor function.
Endotronix, a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure.
GenEp is a biotechnology company developing therapies that address unmet needs in patients with epilepsy.
HistoSonics is a private medical device company whose mission is to redefine cancer treatment with a non-invasive, highly precise, cost-effective method of tumor destruction call Robotically Assisted Sonic Therapy (RAST™), based on the science of histotripsy.
LAVA Medtech Acquisition Corp
LAVA Medtech Acquisition Corp. is a newly incorporated blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses.
LQT Therapeutics is developing therapies for genetic heart diseases pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
Medexus Pharmaceuticals is a leading specialty pharmaceutical company with a strong North American commercial platform. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics.
Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.
OncoMyx utilizes the Myxoma virus as both an oncolytic virus and a vehicle to deliver immunomodulatory proteins to treat a variety of both solid and liquid tumors to achieve the greatest therapeutic benefit for cancer patients.
Based in Montreal, OsteoQC is developing new drug candidates for the treatment of bone-related diseases.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing STS101 as an important and differentiated therapeutic option for the acute treatment of migraine.
Swift Medical is a leader in imaging technology and data analytics solutions for the healthcare industry. Swift Wound, together with Swift’s Metrics dashboard, represents a new generation in wound care management technology.
Aurinia Pharmaceuticals lead drug, LUPKYNIS (voclosporin), was approved in January 2021 as the first oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death
Bardy Diagnostics, an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry was acquired by Hillrom for $375 million in January 2021
Engage Therapeutics is focused on epilepsy patients suffering from uncontrolled seizures with what could be the first rescue treatment with the potential to stop their seizures. The company was acquired by UBC for up to US$270 million in June 2020.
MAKO Surgical Corp.
Lumira was an early investor in MAKO Surgical Corp. prior to its IPO and later when it was acquired by Stryker for $1.65 billion in 2013 for its minimally invasive robotic surgical arm for partial knee and total hip arthroplasty.
Pharmasset was acquired by Gilead in 2011 for $11 billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Zymeworks is a biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.
Alveolus, developer of next generation non-vascular interventional stent technology for use in the lungs, was acquired by Merit Medical Systems Inc. in February 2008.
Ception Therapeutics was acquired by Cephalon Inc. in March 2010 in a deal worth $350 million plus significant future millstones. Cephalon Inc. was subsequently acquired by Teva in 2011.
Corus Pharmaceuticals, developer of Aztreonam for treatment of cystic fibrosis and Lidocaine for treatment of oral corticosteroid dependent asthma, was acquired by Gilead in August 2006 for $365 million.
Lumira Ventures led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005.
Guava Technologies was acquired by Millipore Inc. in February 2009.
From the time we invested in 2002 to our exit in 2006, ISTA Pharmaceuticals launched 3 products in the United States to treat diseases of the eye.
KAI Pharmaceuticals Inc., developer of novel therapeutics for kidney disease, was acquired by Amgen in 2012 for US$315 million.
Morphotek was acquired by Eisai Inc. in April 2007 for $325 million.
Resonant Medical, developer of 3D ultrasound image-guided radiotherapy products, was acquired by Elekta in May of 2010.
Think Research develops knowledge-based and leading clinical content tools that empower clinicians to deliver the best evidence-based care to patients and drive better patient outcomes.
Automated Breast Ultrasound company, U-Systems, was acquired by GE Healthcare Limited in November 2012.